The Claims Defining the Invention are as Follows

1 A method for treatment of a cancer patient in need of treatment, which comprises the steps of:

(i) delivering to said patient on day one of a treatment regime:

(a) a 2-hour infusion of oxaliplatin (**OXA**) at a dose of about 60 to 80 mg/m^2;

(b) a 2-hour infusion of leucovorin (**LV**) at a dose of about 100 to 400 mg/m^2;

(c) followed by a bolus of 5-fluorouracil (**5-FU**) at a dose of about 300 to 500 mg/m^2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m^2; and repeating step (i), if required, then

(ii) delivering selective internal radiation therapy (**SIRT**) to said patient between days 3 to 14 following either the commencement of step (i) or following the repeat of step (i);

(iii) repeating step (i) for three cycles at an interval of one to three weeks between treatment cycles; then

(iv) two weeks after the final treatment delivered in step (iii) delivering to said patient the following treatment:

(a) a 2-hour infusion of OXA at a dose of about 80 to 100 mg/m^2;

(b) a 2-hour infusion of LV at a dose of about 100 and 400 mg/m^2;

(c) followed by a bolus of 5-FU at a dose of about 300 to 500 mg/m^2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m^2.

2 A method according to claim 1 further comprising the step of repeating step (iv) every 2 to 3 weeks, until the cancer is treated.

3 A method according to claim 1 or 2 wherein the dose of OXA used in step (i)(a) is selected from one of the following OXA doses: 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 mg/m^2.

4 A method according to claim 1 or 2 wherein the dose of OXA used in step (iv)(a) is selected from one of the following OXA doses: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mg/m^2.

5 A method according to claim 1 or 2 wherein the dose of LV used in step (i)(b) or (iv)(b) is selected from one of the following LV doses: 100, 110, 120, 130, 140, 150, 160, 170, 180 and 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400 mg/m^2.

6 A method according to claim 1 or 2 wherein the bolus dose of 5-FU used in step (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500 mg/m^2.

7 A method according to claim 1 or 2 wherein the infusion dose of 5-FU used in step (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 2.1, 2.2, 2.3, 2.4 and 2.5 g/m^2.

8 A method according to any one of the preceding claims comprising the step of treating the patient with bevacizumab.

9 A method according to claim 8 wherein bevacizumab is administered at a dose of about 5 to 10 mg/kg.

10 A method according to claim 9 wherein the bevacizumab is delivered to a patient in 30 to 60 minutes.

11 A method according to claim 8 wherein the bevacizumab therapy is delivered to said patient in the last cycle of therapy immediately after OXA therapy.

12 A method according to any one of the preceding claims wherein one or more chemotherapeutic agents additional to those used in the method are incorporated into systemic chemotherapy procedure drugs

13 A method according claim 12 wherein the chemotherapeutic agents are selected from irinotecan or capecitabine.

14 A method according to any one of the preceding claims wherein the patient is also treated with an anti-angiogenesis factor.

15 A method according to any one of the preceding claims wherein the patient receives an amount of SIRT therapy suitable to effectively treat a cancer.

16 A method according to any one of the preceding claims wherein the SIRT therapy is administered using SIR-Spheres™ microspheres.

17 A method according claim16 wherein the prescribed activity of the SIR-Spheres™ microspheres in both lobes of the liver is between 1.2 and 2.4 GBq.

The Claims Defining the Invention are as Follows

1. Use of a combination of oxaliplatin **(OXA)**, leucovorin **(LV)** and 5-fluorouracil **(5-FU)** in the manufacture of a medicament for the treatment of a cancer in a patient in need of treatment,

   (i) wherein the medicament is to be delivered to said patient on day one of a treatment regime comprising:

   (a) a 2-hour infusion of OXA at a dose of about 60 to 80 mg/m^2;

   (b) a 2-hour infusion of LV at a dose of about 100 to 400 mg/m^2;

   (c) followed by a bolus of 5-FU at a dose of about 300 to 500 mg/m^2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m^2; and repeating (i), if required,

   (ii) wherein between days 3 to 14 following either the commencement of (i) or following the repeat of (i), selective internal radiation therapy **(SIRT)** is to be delivered to said patient;

   (iii) wherein (i) is to be repeated for three cycles at an interval of one to three weeks between treatment cycles; and

   (iv) wherein two weeks after the final treatment delivered in (iii), said patient is to be delivered the following treatment:

   (a) a 2-hour infusion of OXA at a dose of about 80 to 100 mg/m^2;

   (b) a 2-hour infusion of LV at a dose of about 100 and 400 mg/m^2;

   (c) followed by a bolus of 5-FU at a dose of about 300 to 500 mg/m^2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m^2.

2. The use according to claim 1, further wherein (iv) is to be repeated every 2 to 3 weeks, until the cancer is treated.

3. The use according to claim 1 or 2, wherein the dose of OXA used in (i)(a) is selected from one of the following OXA doses: 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 mg/m^2.

4. The use according to claim 1 or 2, wherein the dose of OXA used in (iv)(a) is selected from one of the following OXA doses: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mg/m^2.

5. The use according to claim 1 or 2, wherein the dose of LV used in (i)(b) or (iv)(b) is selected from one of the following LV doses: 100, 110, 120, 130, 140, 150, 160, 170, 180 and 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400 mg/m^2.

6. The use according to claim 1 or 2, wherein the bolus dose of 5-FU used in (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500 mg/m^2.

7. The use according to claim 1 or 2, wherein the infusion dose of 5-FU used in (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 2.1, 2.2, 2.3, 2.4 and 2.5 g/m^2.

8. The use according to any one of the preceding claims, further wherein the patient is to be treated with bevacizumab.

9. The use according to claim 8, wherein bevacizumab is to be administered at a dose of about 5 to 10 mg/kg.

10. The use according to claim 9, wherein the bevacizumab is to be delivered to a patient in 30 to 60 minutes.

11. The use according to claim 8, wherein the bevacizumab therapy is to be delivered to said patient in the last cycle of therapy immediately after OXA therapy.

12. The use according to any one of the preceding claims, wherein one or more chemotherapeutic agents additional to those used are incorporated into systemic chemotherapy procedure drugs.

13. The use according claim 12, wherein the chemotherapeutic agents are selected from irinotecan or capecitabine.

14. The use according to any one of the preceding claims, wherein the patient is also to be treated with an anti-angiogenesis factor.

15. The use according to any one of the preceding claims, wherein the patient is to receive an amount of SIRT therapy suitable to effectively treat a cancer.

16. The use according to any one of the preceding claims, wherein the SIRT therapy is to be administered using SIR-Spheres™ microspheres.

17. The use according claim 16, wherein the prescribed activity of the SIR-Spheres™ microspheres in both lobes of the liver is between 1.2 and 2.4 GBq.